Literature DB >> 2137705

Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques.

J Arnt1, J Hyttel.   

Abstract

The effects of the dopamine (DA) D-2 antagonist YM 09151-2 and the DA D-2 agonists terguride, preclamol, EMD 23448, B-HT 920, quinpirole and (-)-NPA were studied in a battery of behavioural tests in order to evaluate their relative efficacies. Furthermore, their affinities for DA D-2 receptors labelled by 3H-N-0437 were measured in vitro. All agonists reduced spontaneous locomotor activity and induced marked contralateral circling behaviour in 6-hydroxy-DA-lesioned rats. Quinpirole and (-)-NPA increased motor activity after high doses. YM 09151-2 did not induce circling. In hemitransected rats quinpirole and (-)-NPA had weak effects when given alone, whereas the other agonists were ineffective. After combination with DA D-1 agonist SK&F 38393, B-HT 920 became effective, and the effects of quinpirole and (-)-NPA were facilitated. EMD 23448, preclamol and terguride were not active. In contrast, the two latter compounds fully inhibited the response to apomorphine. In stereotypy experiments a similar activity pattern was observed. Finally, drug discrimination studies showed that quinpirole, (-)-NPA and B-HT 920 substituted for the stimulus effects induced by d-amphetamine or (-)-NPA in different groups of rats. EMD 23448 induced intermediate effects, whereas preclamol and terguride had weak effects. None of the partial agonists inhibited the response of d-amphetamine. YM 09151-2 potently inhibited the effect of d-amphetamine. The results suggest that DA D-2 agonists can be ranked according to gradually increasing agonist efficacies rather than classified into autoreceptor-selective versus nonselective D-2 agonists. Implications of this hypothesis are discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137705     DOI: 10.1007/bf01245021

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  43 in total

1.  B-HT 920 stimulates postsynaptic D2 dopamine receptors in the normal rat: electrophysiological and behavioral evidence.

Authors:  P A Johansen; D Clarkl; F J White
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

Review 2.  Manipulating the dopaminergic system in Parkinson's disease.

Authors:  A E Lang
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

3.  The intrinsic activity of (-)-3-PPP (preclamol) on pituitary DA receptors in female rats is enhanced following chronic DA depletion.

Authors:  M Carlsson; E Eriksson
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

4.  The discriminative stimulus properties of the D-1 agonist SK&F 38393 and the D-2 agonist (-)-NPA are mediated by separate mechanisms.

Authors:  J Arnt
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

5.  Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors.

Authors:  M Terai; S Usuda; I Kuroiwa; O Noshiro; H Maeno
Journal:  Jpn J Pharmacol       Date:  1983-08

6.  The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of cats.

Authors:  L Pichler; C Pifl; O Hornykiewicz; W Kobinger
Journal:  Eur J Pharmacol       Date:  1987-03-17       Impact factor: 4.432

7.  Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs.

Authors:  E B Nielsen; S A Jepsen
Journal:  Eur J Pharmacol       Date:  1985-05-08       Impact factor: 4.432

8.  Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism.

Authors:  W Kehr
Journal:  Eur J Pharmacol       Date:  1984-01-13       Impact factor: 4.432

9.  Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists.

Authors:  G G Yarbrough; J McGuffin-Clineschmidt; D K Singh; D R Haubrich; R J Bendesky; G E Martin
Journal:  Eur J Pharmacol       Date:  1984-03-16       Impact factor: 4.432

10.  Postsynaptic dopamine agonist properties of TL-99 are revealed by yohimbine co-treatment.

Authors:  G Pastor; S Fallon; J J Welch; J M Liebman
Journal:  Eur J Pharmacol       Date:  1983-03-04       Impact factor: 4.432

View more
  7 in total

1.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

2.  Behavioral effects of dopamine receptor inactivation in the caudate-putamen of preweanling rats: role of the D2 receptor.

Authors:  Taleen Der-Ghazarian; Crystal B Widarma; Arnold Gutierrez; Leslie R Amodeo; Joseph M Valentine; Danielle E Humphrey; Ashley E Gonzalez; Cynthia A Crawford; Sanders A McDougall
Journal:  Psychopharmacology (Berl)       Date:  2013-09-22       Impact factor: 4.530

3.  Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys.

Authors:  Donna M Platt; Joshua S Rodefer; James K Rowlett; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2003-02-13       Impact factor: 4.530

4.  The partial dopamine D2-like receptor agonist terguride functions as an agonist in preweanling rats after a 5-day reserpine regimen.

Authors:  Jennifer J Wacan; Carmela M Reichel; Cristal M Farley; Sanders A McDougall
Journal:  Psychopharmacology (Berl)       Date:  2006-01-31       Impact factor: 4.530

5.  Effects of dorsal striatal infusions of R(-)-propylnorapomorphine on kappa-opioid-mediated locomotor activity in the young rat: possible role of the indirect pathway.

Authors:  S Charntikov; L R Halladay; M S Herbert; E M Marquez; S A McDougall
Journal:  Neuroscience       Date:  2008-06-14       Impact factor: 3.590

6.  Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the prolactin suppression induced by a series of full and partial dopamine D2 receptor agonists in male rats.

Authors:  A Ekman; E Eriksson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-08       Impact factor: 3.000

7.  Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.

Authors:  H L Andersen; I C Kilpatrick
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.